Pathological complete response (pCR), defined as the lack of residual cancer after neoadjuvant chemotherapy (NAC), has been established as a surrogate marker for excellent prognosis of operable breast cancers. Small tumor size, higher tumor grade, and high proliferative activity are significant predictors for a high rate of pCR.[@CR1] However, the sensitivity and specificity of predicting pCR using these clinical factors are not high[@CR2]^,^[@CR3] and the identification of more precise predictive factors is a critical issue.

In addition to the diagnostic ability of ^18^F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT),[@CR4] the usefulness of the maximum standardized uptake value (SUV~max~) on FDG-PET for predicting the prognosis of operable breast cancers is well established.[@CR5]^--^[@CR9] The value of SUV~max~ as a predictive tool for treatment efficacy was reported in metastatic[@CR10] and early breast cancers.[@CR11] In the NAC setting, a significant association between an increased SUV~max~ and a high rate of pCR has been reported.[@CR12]^,^[@CR13] In addition to baseline values, changes in these values after treatment are significantly associated with the response to chemotherapy.[@CR14] Since altered glucose metabolism occurs earlier than tumor shrinkage,[@CR15] it may be possible to evaluate the treatment efficacy as early as after one or two treatment cycles.

SUV~max~ levels have been reported to be inaccurate compared with the actual uptake of FDG, due to the partial volume effect.[@CR16] Since volume-based parameters on FDG-PET, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), evaluate not only metabolic activity but also total tumor burden, recent studies have focused on these metabolic parameters rather than on SUV~max~ for predicting the response to chemotherapy. Although early reductions of SUV~max~ are reportedly associated with improved response to NAC,[@CR17]^,^[@CR18] which metabolic parameter offers the most precise prediction remains unknown. In addition, the superiority of baseline or early response to treatment PET data is also undetermined.

The present study explored the predictive values of SUV~max~, SUV~peak~, SUV~mean~, and volume-based parameters, including MTV and TLG, at baseline in breast cancers treated with primary systemic chemotherapy (PSC). Additionally, early changes in these parameters after treatment were also investigated in terms of their relationships with treatment efficacy.

Patients and Methods {#Sec1}
====================

Patient Recruitment {#Sec2}
-------------------

This retrospective study constitutively recruited a total of 267 breast cancer patients who underwent surgery after preoperative chemotherapy between October 2008 and May 2018. Among these participants, 194 patients who underwent FDG-PET/CT before starting PSC were selected. Since five patients had bilateral breast cancers, we analyzed a total of 199 breast cancers in 194 patients. We evaluated response in the primary sites (breast), and nine patients with stage IV who had PSC followed by operation were also included. We also obtained FDG-PET/CT data after the start of PSC for 69 patients (70 breast cancers).

The Ethics Committee of Hyogo College of Medicine approved the present study (numbers 1818 and 1708), and written informed consent was obtained from all 69 participants who underwent FDG-PET/CT after the start of PSC (number 1708, UMIN000030408). In the remaining patients, only baseline FDG-PET/CT data from clinical practice were used and offered no risk to participants; thus, written informed consent was not required (number 1818).

Chemotherapy Regimen and Evaluation of Pathological Response {#Sec3}
------------------------------------------------------------

Preoperative chemotherapies involving anthracycline-containing, taxane-based, sequential use of anthracycline-containing and taxane, and unspecified regimens were administered in 6, 48, 137, and 3 patients, respectively. Concurrent use of trastuzumab with chemotherapy was administered to 64 patients. Pathological examinations of the whole area of pre-existing breast cancer lesions were performed, and pCR was defined as complete absence of invasive cancer cells in the breast.[@CR19]

^18^F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) Procedure {#Sec5}
------------------------------------------------------------------------------------------------

FDG-PET/CT was performed using a Gemini GXL16 or Gemini TF64 PET/CT scanner (Philips Medical Systems, Eindhoven, The Netherlands) following injection of 4.0 or 3.0 MBq/kg body weight FDG for the GXL16 and TF64, respectively. Scanning images were obtained approximately 60 min after injection, as described previously.[@CR20] The 194 patients underwent FDG-PET/CT examination before starting PSC, of whom 69 (70 breast cancers) underwent a repeat FDG-PET/CT examination after starting chemotherapy. We obtained FDG-PET/CT data after one cycle of PSC (2--3 weeks after the start of chemotherapy), except for one patient whose data were obtained after two cycles (electronic supplementary data).

Imaging Analyses {#Sec6}
----------------

To quantify ^18^F-FDG uptake, the SUVs were measured. We set the volume of interest (VOI) as the area in which FDG accumulated in the breast, along the margin of tumor uptake. The SUV was calculated as the regional radioactivity concentration (Bq/mL)/\[injected dose (Bq)/patient weight (g)\] in the most intense area of ^18^F-FDG accumulation (a region of interest \[ROI\]). We selected the region containing the tumor in which the FDG in the breast was accumulated, as observed on the image, and set a target VOI manually in the breast cancer primary lesion with FDG accumulation. The maximum value of SUV in the VOI was defined as the SUV~max~, and the volume of voxels of ≥ 40% of the SUV~max~ in the VOI was defined as the MTV.[@CR21]^--^[@CR23] The SUV~peak~ was defined as the average activity concentration within a 1 cm^3^ spherical VOI centered on the 'hottest focus' within the primary tumor. The average SUV value in the voxel that showed ≥ 40% was defined as the SUV~mean~ and TLG was defined as MTV × SUV~mean~. These parameters were all automatically calculated by the computer software package GI-PET (AZE Co., Ltd, Tokyo, Japan). Harmonization of data in different PET/CT systems was performed using phantom data.

The percentage changes (∆%) of PET data at baseline and after the start of PSC in each of the five parameters were calculated as follows: percentage change (∆%) = (delayed parameter − baseline parameter)/baseline parameter × 100.

Statistical Analysis {#Sec7}
--------------------

The associations of clinicopathological characteristics between breast cancers that achieved pCR and those that did not were analyzed using the Fisher's exact or Wilcoxon rank-sum tests. The relationships between pCR and levels of each metabolic parameter were calculated using Fisher's exact tests, and logistic regression was used to obtain odds ratios (ORs) and 95% confidence intervals (CIs) by univariable and multivariable analyses of clinical factors or metabolic parameters and pCR. Statistical significance was set at *p* *\<* 0.05. All statistical calculations were performed using JMP Pro 13 (SAS Institute Inc., Cary, NC, USA).

Results {#Sec8}
=======

Relationships Between Clinicopathological Factors and Pathological Response {#Sec9}
---------------------------------------------------------------------------

We defined pCR and non-pCR in 64 and 135 breast cancers, respectively. The pCR rates were significantly higher in those with small tumor size, higher nuclear grade, estrogen receptor (ER)-negative/human epidermal growth factor receptor 2 (HER2)-negative (triple-negative \[TN\]) and HER2-positive subtypes, high levels of Ki67, and an anthracycline and taxane regimen (electronic supplementary Table 1 and data). The SUV~max~, SUV~peak~, and SUV~mean~ were significantly associated with nuclear grade and Ki67 expression levels. There were significant associations between tumor size and all parameters except SUV~max~, and the subtypes were significantly associated with all parameters except TLG. Lymph node metastasis was significantly associated with MTV and TLG (electronic supplementary Table 2).

Determination of the Optimal Cut-Off Values for Pathological Complete Response (pCR) of Metabolic Parameters by PET/CT at Baseline and During Primary Systemic Chemotherapy {#Sec10}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Representative cases of PET imaging are shown in Fig. [1](#Fig1){ref-type="fig"}. The FDG uptake detected in the left breast at baseline was diminished after one cycle of chemotherapy (Fig. [1](#Fig1){ref-type="fig"}a, b) in patients who achieved pCR; however, the uptake of FDG at baseline in the right breast remained after one cycle of chemotherapy (Fig. [1](#Fig1){ref-type="fig"}c, d). The cut-off values of SUV~max~, SUV~peak~, SUV~mean~, MTV, and TLG at baseline for pCR were determined using receiver operating characteristic (ROC) curves calculated using the Youden index for the areas under the curve (AUC) (electronic supplementary Fig. 1). Similar methods were used to determine the cut-off values of the reduction rate in each metabolic parameter for pCR (electronic supplementary Fig. 2).Fig. 1Representative cases of FDG accumulation in breast cancers at baseline and after the start of primary systemic chemotherapy. **a** Baseline and **b** after one treatment cycle in a case of breast cancer that achieved a pCR. **c** Baseline and **d** after one treatment cycle of a case of breast cancer that did not achieve a pCR. *FDG* fluorodeoxyglucose, *pCR* pathological complete response

Associations Between pCR After PSC and Each Metabolic Parameter {#Sec11}
---------------------------------------------------------------

Breast cancers with high baseline levels of SUV~max~, SUV~peak~, and SUV~mean~ had a significantly higher rate of pCR than breast cancers with low levels. However, the frequency of pCR was significantly higher for low baseline levels of MTV and TLG (electronic supplementary Fig. 3). Of these baseline parameters, MTV was the most significant predictor for pCR (47.9% vs. 23.4%; *p* *=* 0.0005).

Similarly, breast cancers with high reduction rates had significantly higher frequencies of pCR for ∆SUV~max~, ∆SUV~peak~, ∆SUV~mean~, and ∆TLG, but not ∆MTV, in which the significance was marginal (electronic supplementary Fig. 4). The difference in pCR rates between the two groups was most significant for the ∆SUV~mean~ (72.2% vs. 23.5%; *p* \< 0.0001).

Univariable and Multivariable Analyses of pCR, Including Metabolic Parameters at Baseline and During Treatment {#Sec12}
--------------------------------------------------------------------------------------------------------------

First, we analyzed data of all 199 breast cancers, including metabolic parameters at baseline. Tumor size, nuclear grade, Ki67 expression levels, subtypes, chemotherapy regimen, and all metabolic parameters at baseline, including SUV~max~, SUV~peak~, SUV~mean~, MTV, and TLG, were significantly associated with pCR in univariable analysis (Table [1](#Tab1){ref-type="table"}). The multivariable analyses included these clinical factors with one of the metabolic parameters. As shown in Table [1](#Tab1){ref-type="table"}, baseline MTV was significantly associated with pCR in multivariable analysis (OR 0.30, 95% CI 0.11--0.84; *p* *=* 0.0212).Table 1Univariable and multivariable analyses of the clinicopathological characteristics and metabolic parameters at baseline for pathological complete response in 199 breast cancers*n*Univariable*p* valueMultivariable*p* value\[OR (95% CI)\]\[OR (95% CI)\]Menopausal status Premenopausal801.00 Postmenopausal1191.59 (0.85--2.96)0.1447T size (cm) ≤ 2.0431.001.00 \> 21560.40 (0.20--0.80)0.00930.40 (0.13--1.20)0.1024Lymph node metastasis Negative1041.00 Positive950.65 (0.36--1.20)0.1677Nuclear grade 1741.001.00 2 + 31155.76 (2.62--12.66)\< 0.00013.14 (1.09--9.04)0.0342Ki67 expression levels^a^ Low501.001.00 High1399.74 (2.89--32.89)0.000220.58 (1.55--237.07)0.0219Subtypes^b^ TN481.001.00 Luminal A310.04 (0.01--0.34)0.00292.23 (0.08--65.78)0.6418 Luminal B490.18 (0.06--0.50)0.00100.20 (0.06--0.67)0.0114 Luminal-HER2360.57 (0.23--1.41)0.21981.18 (0.34--4.09)0.7908 HER2333.43 (1.32--8.91)0.01145.45 (1.53--19.41)0.0089Chemotherapy regimen Taxane481.001.00 Anthracycline and taxane1423.26 (1.42--7.47)0.00532.83 (0.92--8.77)0.0707SUV~max~^c^ Low601.00 High1392.10 (1.04--4.24)0.0396Not includedSUV~peak~^d^ Low621.00 High1372.24 (1.11--4.51)0.0249Not includedSUV~mean~^e^ Low471.00 High1522.84 (1.24--6.52)0.0135Not includedMTV^f^ Low711.00 High1280.33 (0.18--0.62)0.00050.30 (0.11--0.84)0.0212TLG^g^ Low1101.00 High890.43 (0.23--0.81)0.0092Not included*OR* odds ratio, *CI* confidence interval, *TN* triple-negative, *ER* estrogen-receptor, *HER2* human epidermal growth factor receptor 2, *SUV*~*max*~ maximum standardized uptake value, *SUV*~*peak*~ peak standardized uptake value, *SUV*~*mean*~ mean standardized uptake value, *MTV* metabolic tumor volume, *TLG* total lesion glycolysis^a^Low \< 20%, high ≥ 20%^b^TN, ER-negative/HER2-negative; Luminal A, ER-positive/HER2-negative with Ki67 \< 20%; Luminal B, ER-positive/HER2-negative with Ki67 ≥ 20%; Luminal-HER2, ER-positive/HER2-positive; HER2, ER-negative/HER2-positive^c^Low \< 3.664, high ≥ 3.664^d^Low \< 3.279, high ≥ 3.279^e^Low \< 1.782, high ≥ 1.782^f^Low \< 4.416, high ≥ 4.416^g^Low \< 20.138, high ≥ 20.138

Data of metabolic parameters during treatment in 70 breast cancers were further analyzed. All of ∆SUV~max~, ∆SUV~peak~, ∆SUV~mean~, and ∆TLG were significant predictive factors for pCR in the univariable analysis (Table [2](#Tab2){ref-type="table"}). Since the association between pCR and ∆SUV~mean~ was most significant, we performed multivariable analysis, including only ∆SUV~mean~ as a metabolic parameter, and identified ∆SUV~mean~ as a significant and independent factor, as shown in Table [2](#Tab2){ref-type="table"} (OR 8.05, 95% CI 1.45--44.80; *p* *=* 0.0173).Table 2Univariable and multivariable analyses of the clinicopathological characteristics and the reduction of metabolic parameters after the start of chemotherapy for pathological complete response in 70 breast cancers*n*Univariable*p* valueMultivariable*p* value\[OR (95% CI)\]\[OR (95% CI)\]Menopausal status Premenopausal311.00 Postmenopausal391.28 (0.50--3.29)0.6110T size (cm) ≤ 2.0141.001.00 \> 2560.11 (0.02--0.53)0.00600.07 (0.004--1.03)0.0522Lymph node metastasis Negative291.00 Positive410.64 (0.24--1.66)0.3538Nuclear grade 1161.001.00 2 + 35011.42 (2.33--55.88)0.002614.89 (1.07--207.75)0.0446Ki67 expression levels^a^ Low91.00 High588.57 (1.01--72.98)0.0493Not calculatedSubtypes^b^ TN191.001.00 Luminal A7Not calculatedNot calculated Luminal B180.09 (0.02--0.45)0.00300.11 (0.01--0.84)0.0335 Luminal-HER2110.55 (0.12--2.56)0.44940.34 (0.04--3.01)0.3352 HER2141.69 (0.34--8.40)0.51970.71 (0.07--6.79)0.7692Chemotherapy regimen Taxane61.00 Anthracycline and taxane635.50 (0.61--49.80)0.1294∆SUV~max~^c^ Low331.00 High377.39 (2.55--21.39)0.0002Not included∆SUV~peak~^d^ Low331.00 High377.39 (2.55--21.39)0.0002Not included∆SUV~mean~^e^ Low341.00 High368.45 (2.88--24.81)0.00018.05 (1.45--44.80)0.0173∆MTV^f^ Low261.00 High442.49 (0.91--6.79)0.0756Not included∆TLG^g^ Low321.00 High386.50 (2.27--18.62)0.0005Not included*OR* odds ratio, *CI* confidence interval, *TN* triple-negative, *ER* estrogen receptor, *HER2* human epidermal growth factor receptor 2, *SUV*~*max*~ maximum standardized uptake value, *SUV*~*peak*~ peak standardized uptake value, *SUV*~*mean*~ mean standardized uptake value, *MTV* metabolic tumor volume, *TLG* total lesion glycolysis, ∆ reduction rate^a^Low \< 20%, high ≥ 20%^b^TN, ER-negative/HER2-negative; Luminal A, ER-positive/HER2-negative with Ki67 \< 20%; Luminal B, ER-positive/HER2-negative with Ki67 ≥ 20%; Luminal-HER2, ER-positive/HER2-positive; HER2, ER-negative/HER2-positive^c^Low \< − 56.3, high ≥ − 56.3^d^Low \< − 55.1, high ≥ − 55.1^e^Low \< − 55.8, high ≥ − 55.8^f^Low \< − 22.2, high ≥ − 22.2^g^Low \< − 65.0, high ≥ − 65.0

Predictive Ability of pCR for the Combination of Baseline Metabolic Tumor Volume (MTV) and ∆SUV~mean~ Parameters {#Sec13}
----------------------------------------------------------------------------------------------------------------

Since both baseline MTV and ∆SUV~mean~ were significantly associated with pCR, we further analyzed the combination of these parameters. The pCR rate was highest for low baseline MTV and high ∆SUV~mean~ (86.7%), and lowest for high baseline MTV and low ∆SUV~mean~ (15.4%) \[Fig. [2](#Fig2){ref-type="fig"}a\]. Since breast cancers with high baseline MTV and high ∆SUV~mean~, as well as those with low baseline MTV and low ∆SUV~mean~, showed intermediate pCR rates (61.9% and 50%, respectively), we further combined these two intermediate groups in Fig. [2](#Fig2){ref-type="fig"}b (pCR rate 58.6%). In multivariable analysis, the combination of baseline MTV and ∆SUV~mean~ was a significant and independent predictor of pCR (OR 28.63, 95% CI 1.94--422.42; *p* *=* 0.0146 for low baseline MTV and high ∆SUV~mean~) (Table [3](#Tab3){ref-type="table"}). Fig. 2pCR rates according to the combination of MTV at baseline and ∆SUV~mean~. The pCR rates of **a** four groups and **b** three groups after combining both high and both low MTV and ∆SUV~mean~. *pCR* pathological complete response, *MTV* metabolic tumor volume, *SUV*~*mean*~ mean standardized uptake value, *H* high, *L* low, *∆* reduction rateTable 3Univariable and multivariable analyses of the clinicopathological characteristics and the combination of MTV at baseline with the reduction of SUV~mean~ in 70 breast cancers*n*Univariable analysis*p* valueMultivariable analysis^a^*p* value\[OR (95% CI)\]\[OR (95% CI)\]MTV^b^ Low471.001.00 High230.20 (0.07--0.60)0.00430.18 (0.03--1.19)0.0749∆SUV~mean~^c^ Low341.00 High368.45 (2.88--24.81)0.00018.05 (1.45--44.80)0.0173MTV and ∆SUV~mean~ High and low261.001.00 Both high, or both low297.79 (2.13--28.49)0.00196.89 (1.10--43.24)0.0394 Low and high1535.75 (5.73--223.00)0.000128.63 (1.94--422.42)0.0146*MTV* metabolic tumor volume, *SUV*~*mean*~ mean standardized uptake value, *OR* odds ratio, *CI* confidence interval, *pCR* pathological complete response, ∆ reduction rate^a^Adjusted for tumor size, nuclear grade, and subtypes that were significantly associated with pCR by univariable analysis in Table [2](#Tab2){ref-type="table"}^b^Low \< 4.416, high ≥ 4.416^c^Low \< − 55.8, high ≥ − 55.8

Discussion {#Sec14}
==========

The results of the present study demonstrated that low levels of baseline MTV and early reduction of SUV~mean~ after the start of treatment were significant and independent predictive factors for a higher rate of pCR in breast cancers treated with PSC. The combination of both parameters predicts pCR more precisely compared with that of baseline MTV or ∆SUV~mean~ alone. The SUV~max~ was a significant predictor of pCR after NAC in 273 breast cancers (OR per one-unit increase 1.09, 95% CI 1.02--1.16; *p* *=* 0.008).[@CR24] However, consistent with our study, SUV~max~, SUV~peak~, and SUV~mean~ at baseline were not associated with pathological response in previous studies.[@CR21]^,^[@CR25]^--^[@CR29] Contrary to SUVs, MTV is a volume-based metabolic parameter that represents both metabolic activity and total tumor burden in each tumor. However, Cho et al. reported no significant association between pCR and baseline TLG or MTV values.[@CR27] Although Cheng et al. reported no correlation between TLG and pCR,[@CR21] baseline MTV was marginally associated with pCR in the HER2-negative group (*n* *=* 30; *p* *=* 0.081). The reason for this discrepancy may be the smaller number of participants (*n* *=* 26 and *n* *=* 30) compared with our study (*n* *=* 199).

Although SUV~max~ levels at baseline and after one cycle were not correlated with pCR in 50 TN breast cancers, higher ∆SUV~max~ values were significantly associated with increased pCR in multivariable analysis (OR 7.1; *p* *=* 0.014).[@CR30] Similarly, early changes in SUV~max~ corrected for lean body mass (SUL~max~) values between those achieving pCR and those not achieving pCR differed significantly in 59 HER2-negative breast cancers (63.0% vs. 32.9%; *p* *=* 0.003).[@CR31] Further studies demonstrated that not at baseline, but rather ∆SUV~max~ after the start of NAC, was significantly associated with pCR.[@CR25]^,^[@CR28]^,^[@CR29]^,^[@CR32]^,^[@CR33] In addition, the mean percentage of ∆TLG~30%~ (*p* *=* 0.005), but not ∆MTV~30%~ (*p* *=* 0.262), was significantly greater in the pCR group[@CR27]; however, neither ∆TLG nor ∆MTV were significantly associated with pCR in the report by Cheng et al.[@CR21] Despite the significant correlation between tumor size reduction rate and the reduction rates of MTV (*p* *=* 0.0004) or TLG (*p* *=* 0.002), but not SUV~max~ (*p* *=* 0.07),[@CR34] the ∆MTV and ∆TLG might be less useful than ∆SUV~max~ when considering their pCR predicting ability.

Groheux et al. reported the AUC of pCR prediction increased from 0.63 to 0.76 when combined ∆SUV~max~ with genomic grade index (GGI; *p* *=* 0.016) in TN breast cancer patients.[@CR28] We identified the significance of the combination of baseline MTV and ∆SUV~mean~ in terms of pCR prediction. Interestingly, MTV was significantly associated with tumor size, but not with grade. Conversely, SUV~max~ was significantly associated with grade, but not with tumor size.[@CR33] Thus, MTV and ∆SUV may be a useful combination for predicting pCR mediating through different mechanisms. Small metabolic tumor size evaluable by MTV and high reduction rate of metabolic activity evaluable by SUV~mean~ may be linked to achieving a pCR. We obtained data regarding metabolic parameters after treatment in 22 breast cancers; all six breast cancers that retained FDG uptake had non-pCR. Even though FDG uptake diminished after treatment, 5 of 16 (31.3%) breast cancers were defined as non-pCR (electronic supplementary data). Thus, the data obtained after treatment may not improve the ability to predict pCR.

We set the optimal cut-off values of ∆SUV~max~, ∆SUV~peak~, and ∆SUV~mean~ at 56.3%, 55.1%, and 55.8%, respectively, and the predictive values of these metabolic parameters were similar. Previous studies reported ∆SUV~max~ cut-off values ranging from 50 to 82.2%.[@CR35] In addition, we used the average SUV value in the voxel that showed ≥ 40% of SUV~max~ as the SUV~mean~, as used in previous studies.[@CR21]^--^[@CR23] In other studies, thresholds of VOI were set to values between 30 and 50%.[@CR27] Although the best threshold was unknown, we obtained similar results when calculated with other cut-off values and the reproducibility of SUV~mean~ measurement was confirmed by a coauthor (data not shown). Issues regarding which parameter of SUV is most useful, and the best optimal cut-off value or threshold, require confirmation in future studies. In addition, we concluded, based on 70 breast cancers, that the sample size was not enough. Further studies involving large numbers of participants are needed. To our knowledge, this is the first study to demonstrate the useful combination of metabolic parameters obtained by PET for pCR in breast cancers treated with preoperative chemotherapy.

Conclusions {#Sec15}
===========

The combination of baseline MTV and ∆SUV~mean~ precisely predicted the pCR in breast cancers treated with chemotherapy. The predictive value of this combination was independent and strong compared with that of other clinical factors, including tumor size, tumor grade, Ki67 levels, and subtypes. Small metabolic tumor size evaluable by MTV, and a high metabolic activity reduction as determined by SUV~mean~, might be useful for predicting improved pCR in breast cancers treated with preoperative chemotherapy.
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